Loading clinical trials...
Loading clinical trials...
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Conditions
Interventions
SHP626
Placebo
Locations
65
United States
Southern California Research Center
Coronado, California, United States
Fresno Clinical Research Center
Fresno, California, United States
Ceders-Sinai Medical Center
Los Angeles, California, United States
California Liver Research Institute
Pasadena, California, United States
Inland Empire Liver Foundation
Rialto, California, United States
South Denver Gastroenterology, PC
Englewood, Colorado, United States
Start Date
October 24, 2016
Primary Completion Date
July 27, 2018
Completion Date
July 27, 2018
Last Updated
November 25, 2019
NCT06819917
NCT06661655
NCT03151473
NCT05623150
NCT06519448
NCT02754037
Lead Sponsor
Mirum Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions